Made possible by charitable contributions from
Navigation Tip: Click on blue text that’s italicized, underlined and in bold for link to more information.
With the month of August winding down to a close, we hope that you’re doing well as we approach
September – Prostate Cancer Awareness Month
It's the perfect time to give a
special shout out of appreciation to Dr. Gerald Chodak and Dr. Mark Moyad
or sharing their medical expertise each month in every issue of the
. Thank you, gentlemen!
We’re especially pleased to send you the
September 2018 issue of the Hot SHEET
newsletter featuring the introduction of
Between the Sheets
– a new advice column created by experts to help men and women with
answers to questions about sexual health and intimacy challenges
that can result from prostate cancer treatment. This content is in response to results from a recent survey to support group leaders that identified intimacy and sexual health as underrepresented prostate cancer educational topics.
We’ll feature a
special presentation on sex and intimacy
relative to prostate cancer, led by Dr. Anne Katz, at the next
Prostate Cancer Pathways for Patients and Caregivers in Englewood, NJ, on Saturday, September 29.
This free event/webcast will also include presentations from Dr. Charles Drake, Dr. Stacy Loeb, and Dr. Mazyar Ghanaat providing content for managing prostate cancer that’s newly diagnosed, recurring, or advanced.
Get more information and register to attend
in person, or watch the online webcast with live audio and video from the event.
We’d also like to call your attention to a variety of
- The Inspire online prostate cancer community
- “A Forum for Her” conference calls for female caregivers of patients with prostate cancer
- Support group calls for newly diagnosed and advanced disease in collaboration with Answer Cancer Foundation
- LivingWith - a new FREE app for mobile devices to help manage life with cancer
The Institute for Clinical and Economic Review (ICER) is an independent nonprofit organization that works to assess the clinical effectiveness and value of drugs.
ICER has released their draft report on anti-androgen drugs for high-risk prostate cancer
that includes enzalutamide (Xtandi®, Astellas and Medivation), abiraterone acetate (Zytiga®, Janssen), and apalutamide (Erleada™, Janssen).
for stakeholder feedback
received during the public comment period and corresponding responses from ICER. Stakeholders will have another opportunity to
offer verbal comments on the report
at a public meeting in Chicago on Thursday, September 13.
and follow the directions in order to secure a position during the public comment period. Please participate as it’s important for ICER to hear from members of the prostate cancer community who are impacted by their report.
Next month we encourage you to
raise awareness for prostate cancer by sharing disease
facts and statistics
in conversations, on social media, or at local festivals, health fairs or events. Let us know if we can assist by providing materials or information.
“Awareness is the greatest agent for change.”
This is a team effort. We appreciate the dedication and commitment from everyone across the country as we work together to raise awareness for prostate cancer during September and throughout the months that follow – thank you!
All the best,
Chuck Strand, Chief Executive Officer
Jackie Konieczka, Office Manager
Terri Likowski, Program Director - Support Group Services
Tim Mix, Communications Manager
Amy Woods, Director of Development
Connect with Us TOO on Social Media: